Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study.
暂无分享,去创建一个
Susan M. Chang | W. Yung | M. Prados | M. Mehta | K. Hess | H. Fine | T. Cloughesy | I. Pollack | D. Schiff | K. Fink | M. Nicholas | W. Yung | K. Jaeckle | J. Kuhn | H. Greenberg
[1] A. Kyritsis,et al. The treatment of recurrent cerebral gliomas with all-trans-retinoic acid (tretinoin) , 1997, Journal of Neuro-Oncology.
[2] W. Yung,et al. All-trans-retinoic acid: a phase II radiation therapy oncology group study (RTOG 91-13) in patients with recurrent malignant astrocytoma , 1997, Journal of Neuro-Oncology.
[3] L. Stewart,et al. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials , 2002, The Lancet.
[4] C. Monville,et al. Retinoic acid increases proliferation rate of GL‐15 glioma cells, involving activation of STAT‐3 transcription factor , 2002, Journal of neuroscience research.
[5] F. Recchia,et al. Ifosfamide, cisplatin, and 13‐Cis retinoic acid for patients with advanced or recurrent squamous cell carcinoma of the head and neck , 2001, Cancer.
[6] M. J. van den Bent,et al. Temozolomide chemotherapy in recurrent oligodendroglioma , 2001, Neurology.
[7] E. Frenkel,et al. Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice. , 2001, Cancer research.
[8] C. Fages,et al. Effects of a novel synthetic retinoid on malignant glioma in vitro: inhibition of cell proliferation, induction of apoptosis and differentiation. , 2001, European journal of cancer.
[9] E. Brown,et al. Agonists of the retinoic acid- and retinoid X-receptors inhibit hepatocyte growth factor secretion and expression in U87 human astrocytoma cells. , 2001, Brain research. Molecular brain research.
[10] S. Schold,et al. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] N. Barth,et al. Interferon-alpha2a and 13-cis-retinoic acid with radiation treatment for high-grade glioma. , 2001, Neuro-oncology.
[12] D. Osoba,et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse , 2000, British Journal of Cancer.
[13] Y. Luo,et al. All trans-retinoic acid suppresses in vitro growth and down-regulates LIF gene expression as well as telomerase activity of human medulloblastoma cells. , 2000, Anticancer research.
[14] G. Sica,et al. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study. , 2000, Anticancer research.
[15] C. Fages,et al. Effects of retinoic acid and tumor necrosis factor alpha on GL‐15 glioblastoma cells , 2000, Neuroreport.
[16] P. Black,et al. Retinoids inhibit human glioma cell proliferation and migration in primary cell cultures but not in established cell lines. , 2000, Neurosurgery.
[17] L. Barré,et al. Pharmacokinetics of all-trans retinoic acid, 13-cis retinoic acid, and fenretinide in plasma and brain of Rat. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[18] M. Álvarez-Dolado,et al. Retinoic acid and 1,25‐dihydroxyvitamin D3 inhibit tenascin‐C expression in rat glioma C6 cells , 1999, Journal of neuroscience research.
[19] Susan M. Chang,et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] M J Gleason,et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] C. Daumas-Duport,et al. Retinoic acid modulates RAR alpha and RAR beta receptors in human glioma cell lines. , 1999, Anticancer research.
[22] D. Thomas,et al. Sensitivity of short-term cultures derived from human malignant glioma to the anti-cancer drug temozolomide. , 1999, Anti-cancer drugs.
[23] J. Jiricny,et al. Involvement of the mismatch repair system in temozolomide-induced apoptosis. , 1998, Molecular pharmacology.
[24] L. Frati,et al. Advanced carcinoma of the pancreas: phase II study of combined chemotherapy, beta-interferon, and retinoids. , 1998, American journal of clinical oncology.
[25] H. Mugishima,et al. [Treatment results of intermittent and cyclic regimen with ATRA and chemotherapy in childhood acute promyelocytic leukemia. Children's Cancer and Leukemia Study Group]. , 1997, [Rinsho ketsueki] The Japanese journal of clinical hematology.
[26] C. Ackerley,et al. Retinoic acid and the cyclin dependent kinase inhibitors synergistically alter proliferation and morphology of U343 astrocytoma cells , 1997, Oncogene.
[27] W. Yung,et al. Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[28] M. Berger,et al. Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[29] M. Dolan,et al. Activity of temozolomide in the treatment of central nervous system tumor xenografts. , 1995, Cancer research.
[30] H. Fine,et al. Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.
[31] T. Cascino,et al. Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] M. Stevens,et al. Anti-tumour imidazotetrazines. Part XXI. Mitozolomide and temozolomide: probes for the major groove of DNA. , 1990, Anti-cancer drug design.
[33] S P Langdon,et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. , 1987, Cancer research.